There is increased industry focus on the behavioral symptoms of Alzheimer’s disease (AD), including agitation—and with good reason. Agitation affects the majority of diagnosed AD patients,…
Market Outlook: Despite advancements in the treatment landscape for first-line CLL with targeted agents such as Imbruvica, Zydelig, and Gazyva/Gazyvaro, it remains largely an incurable disease…
Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), is a leading cause of visual impairment and blindness in the United States and Europe. Degradation of cells…
Dravet syndrome (DS) is a rare, severe, pediatric-onset form of epilepsy characterized by developmental delay or regression and multiple seizure types. Only Diacomit (Biocodex’s stiripentol) is…
Osteoarthritis (OA) is a painful, degenerative condition that is characterized by the gradual development of joint pain, as well as joint stiffness and limitation of movement in the joints. Of…
Although motor fluctuations in Parkinson’s disease (PD) can be managed effectively in the early stages of the disease, today’s treatment paradigm is suboptimal owing to the considerable pill…
Treatment of BRAF-mutation-positive unresectable or metastatic malignant melanoma has been transformed in recent years by the identification of BRAFmutations and the development of BRAF and MEK…
Prior to 2016, the therapeutic landscape for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) had only benefited from the introduction of one novel treatment, Erbitux,…
There are limited treatment options for patients with advanced/metastatic, triple-negative breast cancer because commonly used treatments in other breast cancer segments (i.e., hormonal therapies…
The therapeutic landscape for second-line chronic lymphocytic leukemia (CLL) has benefited from the introduction of three new therapies since 2014, namely, Imbruvica, Venclexta, and Zydelig…
No disease-modifying therapies (DMTs) are approved for nonrelapsing, progressive forms of MS, which comprise the majority of chronic progressive multiple sclerosis (CP-MS) patients. Current…
Although TNF-α inhibitors revolutionized the treatment landscape for moderate to severe Crohn’s disease (CD), considerable unmet need remains. For instance, a notable percentage of patients do…
Type 2 diabetes (T2D) is a complex metabolic disorder characterized by a declining ability to produce or utilize insulin. The chronic and progressive nature of the disease, as well as its…
The positive symptoms of schizophrenia (e.g., hallucinations, delusions) are a symptom domain of schizophrenia that affects approximately 83% of the 3.2 million diagnosed prevalent cases of…
Decision Resources Group (DRG) estimates that 80% of the more than 3 million diagnosed prevalent cases of schizophrenia within our surveyed markets (i.e., United States, France, Germany, and United…